Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Return on Equity (2022 - 2025)

Historic Return on Equity for Prime Medicine (PRME) over the last 4 years, with Q3 2025 value amounting to 1.79%.

  • Prime Medicine's Return on Equity fell 6600.0% to 1.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.79%, marking a year-over-year decrease of 6600.0%. This contributed to the annual value of 1.37% for FY2024, which is 4900.0% down from last year.
  • Latest data reveals that Prime Medicine reported Return on Equity of 1.79% as of Q3 2025, which was down 6600.0% from 2.38% recorded in Q2 2025.
  • Prime Medicine's 5-year Return on Equity high stood at 0.73% for Q2 2022, and its period low was 2.61% during Q4 2022.
  • Moreover, its 4-year median value for Return on Equity was 1.11% (2024), whereas its average is 1.02%.
  • Within the past 5 years, the most significant YoY rise in Prime Medicine's Return on Equity was 14000bps (2023), while the steepest drop was -14900bps (2023).
  • Quarter analysis of 4 years shows Prime Medicine's Return on Equity stood at 2.61% in 2022, then soared by 54bps to 1.21% in 2023, then increased by 6bps to 1.14% in 2024, then tumbled by -57bps to 1.79% in 2025.
  • Its Return on Equity was 1.79% in Q3 2025, compared to 2.38% in Q2 2025 and 1.55% in Q1 2025.